The Latest Breaking News from GSK

Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach for its vaccines.

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

GSK raised its outlook for the second time this year on the back of a strong launch for its RSV vaccine. But GSK stock fell.

Victorians have been warned to prepare for the possibility of thunderstorm asthma again this season.

The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma (ALPMY), Sanofi (SNY), and GSK (GSK) to one’s watchlist could be wise. Keep reading.

A vaccine against tuberculosis has never been closer to reality. But development slowed due to corporate interests

The World Health Organization has authorized a second malaria vaccine in a decision that could offer countries a cheaper and more effective option than the world’s first shot against the parasitic disease

GSK-controlled company works on developing patient-administered treatment by end of the decade

This week, the UN convinced companies to report new nature-related disclosures.